Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disoproxil fumarate

This page shows the latest tenofovir disoproxil fumarate news and features for those working in and with pharma, biotech and healthcare.

ViiV takes on Gilead’s PReP dominance with HIV injectable data

ViiV takes on Gilead’s PReP dominance with HIV injectable data

emtricitabine/tenofovir disoproxil fumarate). ... Gilead is trying to position its recently-approved two-drug combination Descovy (emtricitabine/tenofovir alafenamide) as a successor to Truvada that is safer, with significant improvements on measures of

Latest news

  • Gilead builds case for Descovy PrEP after FDA approval Gilead builds case for Descovy PrEP after FDA approval

    Descovy (emtricitabine/tenofovir alafenamide) claimed its  FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green

  • Gilead claims FDA okay for Descovy as second PrEP option Gilead claims FDA okay for Descovy as second PrEP option

    Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing

  • MSD claims EU approval for two HIV products MSD claims EU approval for two HIV products

    The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,

  • ViiV chalks up another win for two-drug HIV regimen ViiV chalks up another win for two-drug HIV regimen

    effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... fumarate and emtricitabine – two

  • GSK two-drug trial in untreated HIV raises Gilead rivalry GSK two-drug trial in untreated HIV raises Gilead rivalry

    The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics